Featured Publications
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nature Communications 2022, 13: 1547. PMID: 35301314, PMCID: PMC8930970, DOI: 10.1038/s41467-022-29104-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionVirologic responsePersistent SARS-CoV-2 infectionResistance mutationsPre-treatment specimensB-cell deficiencyRemdesivir resistanceRemdesivir therapyViral sheddingCase reportAntiviral agentsPatientsCombinatorial therapyInfectionTherapyWhole-genome sequencingTreatmentImportance of monitoringDe novo emergenceFold increaseRNA-dependent RNA polymeraseNovo emergencePotential benefitsMutationsIndolent
2022
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent studyBorrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient
Gandhi S, Narasimhan S, Workineh A, Mamula M, Yoon J, Krause PJ, Farhadian SF. Borrelia miyamotoi Meningoencephalitis in an Immunocompetent Patient. Open Forum Infectious Diseases 2022, 9: ofac295. PMID: 35873293, PMCID: PMC9301576, DOI: 10.1093/ofid/ofac295.Peer-Reviewed Original Research
2013
Evolution of an Attenuated HIV-1 Isolate in an Elite Suppressor
Salgado M, Gandhi S, Buckheit R, Berkenblit G, Blankson J. Evolution of an Attenuated HIV-1 Isolate in an Elite Suppressor. AIDS Research And Human Retroviruses 2013, 30: 284-288. PMID: 24117037, PMCID: PMC3938915, DOI: 10.1089/aid.2013.0229.Peer-Reviewed Original Research
2007
Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors
Gandhi S, Siliciano J, Bailey J, Siliciano R, Blankson J. Role of APOBEC3G/F-Mediated Hypermutation in the Control of Human Immunodeficiency Virus Type 1 in Elite Suppressors. Journal Of Virology 2007, 82: 3125-3130. PMID: 18077705, PMCID: PMC2259015, DOI: 10.1128/jvi.01533-07.Peer-Reviewed Original ResearchConceptsElite suppressorsAntiretroviral therapyHuman immunodeficiency virus type 1 (HIV-1) replicationHIV-1-infected individualsHuman immunodeficiency virus type 1Immunodeficiency virus type 1Control of viremiaActive antiretroviral therapyType 1 replicationVirus type 1Host defense mechanismsViral loadCopies/Clinical significanceAPOBEC3 activityType 1APOBEC3 familyViremiaPatientsTherapyProviral genomeCytidine deaminasesF proteinDefense mechanismsNovel assay